BP
WX

Banyan Partners’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Banyan Partners’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-14,890
Closed -$549K – 403
2014
Q1 		$549K Sell
14,890
-11,930
-44% -$438K 0.05% 289
2013
Q4 		$1.03M Buy
+26,820
New +$847K 0.07% 228

Other funds holding WX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Banyan Partners's WX Position: Q2 2014 in Review

Banyan Partners sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q2 2014, closing a stake of 14,890 shares — an estimated $549K sold.

Banyan Partners first reported a position in WX in Q4 2013 and held it in 2 quarters. The position peaked at $1.03M in Q4 2013. 154 funds tracked by Wall St. Rank hold WX as of Q2 2014.

  • Banyan Partners reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q2 2014 after selling out during the quarter.
  • Banyan Partners sold 14,890 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q2 2014, an estimated $549K.
  • Banyan Partners first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2013 and held it in 2 quarters.
  • Banyan Partners's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $1.03M in Q4 2013.
  • 154 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q2 2014.

Based on Banyan Partners's 13F filing for Q2 2014, filed 8 Aug 2014.